Healthcare / Medical Instruments & SuppliesShanghai
$13.92
+0.38 (+2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-48.9M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
69.6x
↑EV/EBITDA
13.7x
↑ROE
4.0%
↑Gross Margin
41.4%
↓Debt/Equity
0.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.6%
FCF CAGR
—
FCF margin
12.0%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $564.0M · net income $48.2M · FCF $67.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $564.0M | $564.0M | $558.7M | $463.1M | $609.8M |
| Net Income | $48.2M | $48.2M | $75.6M | $34.8M | $87.7M |
| EBITDA | $143.2M | $143.2M | $183.1M | $127.8M | $172.5M |
| EPS | 0.35 | 0.35 | 0.55 | 0.25 | 0.63 |
| Gross Margin | 41.4% | 41.4% | 41.4% | 30.6% | 31.8% |
| Operating Margin | 19.3% | 19.3% | 22.2% | 12.2% | 17.2% |
| Net Margin | 8.6% | 8.6% | 13.5% | 7.5% | 14.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.32 | 0.32 | 0.31 | 0.29 | 0.28 |
| Current Ratio | 8.14 | 8.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $67.7M | $67.7M | $-56.7M | $-48.9M | $-7.0M |
| Returns | |||||
| ROE | 4.0% | 4.0% | 6.4% | 3.0% | 7.7% |
| Valuation | |||||
| P/E | 69.60 | 69.60 | 21.91 | 66.88 | 39.22 |
| EV/EBITDA | 13.67 | 13.67 | 9.49 | 16.64 | 18.34 |
| P/B | 1.58 | 1.58 | 1.41 | 2.01 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | 1.0% | 1.0% | 20.6% | -24.1% | — |
| EPS Growth | -36.4% | -36.4% | 120.0% | -60.3% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.2%
EPS terminal req.
$1.24
Spread vs growth
-88.6%
5Y implied EPS CAGR
33.7%
EPS terminal req.
$1.49
Spread vs growth
-70.1%
10Y implied EPS CAGR
21.3%
EPS terminal req.
$2.41
Spread vs growth
-57.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.8%
Start / end P/E
27.9x → 40.7x
EPS bridge
0.55 → 0.35
Residual
-16.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.